<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108846</url>
  </required_header>
  <id_info>
    <org_study_id>S-CitAD</org_study_id>
    <secondary_id>R01AG052510</secondary_id>
    <nct_id>NCT03108846</nct_id>
  </id_info>
  <brief_title>Escitalopram for Agitation in Alzheimer's Disease</brief_title>
  <acronym>S-CitAD</acronym>
  <official_title>Escitalopram for Agitation in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of escitalopram for
      agitation in Alzheimer's dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to examine the efficacy and safety of escitalopram as treatment for
      agitation in Alzheimer's dementia (AD) patients. Participants with clinically significant
      agitation, and their caregiver(s), will receive a structured psychosocial intervention.
      Participants not showing a response three weeks later will be randomized 1:1 to escitalopram
      (up to 15 mg/day) or a matching placebo. Participants will receive study drug for 12 weeks,
      with in-person visits at weeks 3, 6, 9, and 12, and with telephone contacts between in-person
      visits. Following the 12-week study treatment period, participants will be followed for
      another 12 weeks without receiving study drug. Participants who do show a response to the
      psychosocial intervention will not be randomized to study drug but will be followed for the
      24-week follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Over-encapsulation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>modified- Alzheimer's Disease Cooperative Study--Clinical Global Impression of Change (mADCS-CGIC)</measure>
    <time_frame>after 12 weeks</time_frame>
    <description>Clinical Global Impression of Change</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-3 capsules each containing placebo only once per day in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>5-15 mg/day (target: 15mg/day if tolerated)</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Masked placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>non-applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Alzheimer's dementia diagnosed clinically by the National Institute on Aging (NIA) and
             the Alzheimer's Association (AA) (2011 NIA/AA criteria)

          2. Mini‐Mental State Examination (MMSE) score of 5‐28 inclusive

          3. Meets the International Psychogeriatric Association provisional criteria for agitation
             in cognitive disorders

          4. Moderate or more severe agitation as measured by a score of ≥ 4 on the
             Neuropsychiatric Inventory-Clinician Rating (NPI‐C), agitation or aggression domain

          5. Provision of informed consent for participation in the study by both caregiver and
             participant (or, if participant is unable to provide informed consent, with surrogate
             consent and participant assent)

          6. Availability of a caregiver who spends at least several hours per week with the
             participant, supervises his/her care, is willing to accompany the participant to study
             visits, and is willing to participate in the study

          7. Stable (for ≥ 14 days) dosing of antipsychotics for agitation or psychosis, if being
             used at all

          8. A medication for agitation is appropriate, in the opinion of the study physician

        Exclusion criteria

          1. Has major depression, as indicated by the following:

               -  Major depressive episode in the past 90 days (meeting the Diagnostic and
                  Statistical Manual of Mental Disorders, 5th Edition (DSM-V) criteria), or

               -  Patient Health Questionnaire-9 (PHQ-9) score ≥ 10 at enrollment

          2. Presence of another brain disease that fully explains the dementia, (e.g., extensive
             brain vascular disease, Parkinson's disease, dementia with Lewy bodies, traumatic
             brain injury, or multiple sclerosis)

          3. Residence in a skilled nursing or Long-Term Acute Care facility

          4. Contraindication to treatment with escitalopram as determined by a study physician,
             such as recent (30 days) use of monoamine oxidase inhibitors (MAOIs) or potential
             participant is hypersensitive to escitalopram or citalopram or any inactive
             ingredients

          5. Prior failed treatment attempt with citalopram or escitalopram for agitation after
             adequate trial, at minimally accepted dose

          6. Indication for psychiatric hospitalization or acute suicidality, in the opinion of the
             study physician

          7. Recent (30 days) changes in treatment for AD (such as cholinesterase inhibitors or
             memantine), including starting, stopping, or dosage modifications

          8. Recent (30 days) use of lorazepam &gt; 0.5 mg daily or use exceeding 3 days per week on
             average

          9. Recent (&lt; 14 days) changes in antipsychotics (including brexpiprazole), or psychosis
             (delusions or hallucinations) requiring a new or change in antipsychotic treatment (in
             the opinion of the study physician)

         10. Abnormal corrected QT interval using Bazett's formula (QTcB) as determined on
             enrollment ECG (defined as &gt; 450 ms for men and &gt; 470 ms for women)

         11. Recent (30 days) presence of severely reduced renal function (as identified by a
             Glomerular filtration rate (GFR) clearance &lt; 30 mL/min) or reduced hepatic function

         12. Current treatment (within 7 days) with any of the following:

               -  anticonvulsants (other than Dilantin for seizures)

               -  antidepressants (other than trazodone, ≤ 50 mg per day at bedtime)

               -  benzodiazepines (other than lorazepam), or

               -  psychostimulants

         13. Recent (&lt; 14 days) changes in Dextromethorphan/quinidine, prazosin, and pimavanserin

         14. Recent (&lt; 14 days) use of medical marijuana

         15. Current participation in a clinical trial or in any study that may add a significant
             burden or affect neuropsychological or other study outcomes

         16. Significant communicative impairments that would affect participation in a clinical
             trial

         17. Any condition that, in the opinion of the study physician, makes it medically
             inappropriate or risky for the potential participant to enroll in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>109 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantine Lyketsos, MD, MHS</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dave Shade, JD</last_name>
    <phone>4109558175</phone>
    <email>dshade@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Ehrhardt, MD</last_name>
    <phone>4109558175</phone>
    <email>sehrhar6@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barrow Neurological Institute/St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynda Seal</last_name>
      <phone>602-406-3386</phone>
      <email>nda.seal@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Marwan Sabbagh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Biomedical Research Foundation</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prasad Padala</last_name>
      <email>ppadala@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anusha Majagi</last_name>
      <email>Anusha.Majagi@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Prasad Padala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles/VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theresa Narvaez</last_name>
      <email>Theresa.Narvaez@va.gov</email>
    </contact>
    <investigator>
      <last_name>David Sultzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California Keck School of Medicine Memory and Aging Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauricio Becerra, MD</last_name>
      <phone>323-442-7594</phone>
      <email>mjbecerr@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Lon S. Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Pawluczy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Atlantic University; Comprehensive Center for Brain Health</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katty Saravia</last_name>
      <phone>561-297-4802</phone>
      <email>saraviak@health.fau.edu</email>
    </contact>
    <investigator>
      <last_name>James Galvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Health Systems</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Gomez</last_name>
      <phone>305-751-8626</phone>
      <phone_ext>64101</phone_ext>
      <email>agomez@miamijewishhealth.org</email>
    </contact>
    <investigator>
      <last_name>Marc Agronin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland, School of Medicine, Clinical Neurobehavioral Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Kolesnik</last_name>
      <phone>667-214-2003</phone>
      <email>OKolesni@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence Adler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheppard Pratt Health System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marylu Ortiz</last_name>
      <phone>410-938-3135</phone>
      <email>mortiz@sheppardpratt.org</email>
    </contact>
    <investigator>
      <last_name>Scott Tyler Aaronson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine, Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nimra Jamil</last_name>
      <phone>410-550-9022</phone>
      <email>njamil2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer Disease Center</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dora Eugene</last_name>
      <phone>617-302-6388</phone>
      <email>dora@thealzcenter.org</email>
    </contact>
    <investigator>
      <last_name>Anil Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Program for Positive Aging</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Molly Turnwald</last_name>
      <phone>734-232-0393</phone>
      <email>turnwald@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Helen Kales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica D'Antonio</last_name>
      <phone>646-774-8674</phone>
      <email>dpd3@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Davangere P. Devanand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Pelton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monroe Community Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14559</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Salem-Spencer, BSN</last_name>
      <phone>585-760-6262</phone>
      <email>Ssalem-Spencer@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Anton Porsteinsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brooke Eiginger</last_name>
      <phone>614-293-9023</phone>
      <email>Brooke.Eiginger@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Scharre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer Disease Research Center; University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Henderson</last_name>
      <phone>412-692-2703</phone>
      <email>hendersonpl@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Oscar Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates, Ltd</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denise Gallagher</last_name>
      <phone>215-957-9250</phone>
      <phone_ext>3284</phone_ext>
      <email>denisegallagher.ana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Weisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Healthcare</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Awkar</last_name>
      <phone>843-724-2219</phone>
      <email>anthony.awkar@rsfh.com</email>
    </contact>
    <investigator>
      <last_name>Jacobo Mintzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor AT&amp;T Memory Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Vilayvanh</last_name>
      <phone>214-818-0380</phone>
      <email>Brian.Vilayvanh@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Cindy Marshall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary and Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramnik Sekhon</last_name>
      <phone>(403) 210-7737</phone>
      <email>ramnik.sekhon@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Zahinoor Ismail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lawson Health Research Institute/Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luli Pallaveshi</last_name>
      <phone>(519) 455-5110</phone>
      <phone_ext>47326</phone_ext>
      <email>Luli.Pallaveshi@sjhc.london.on.ca</email>
    </contact>
    <investigator>
      <last_name>Amer Burhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuropsychopharmacology Research Group, Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janelle Bradley</last_name>
      <phone>(416) 480-6100</phone>
      <phone_ext>2241</phone_ext>
      <email>jbradley@sri.utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Krista Lanctot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruce Pollock, MD</last_name>
      <email>bruce_pollock@camh.net</email>
    </contact>
    <contact_backup>
      <last_name>Abir Khoury</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>33082</phone_ext>
      <email>Abir.Khoury@camh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Bruce Pollock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Memory and Aging</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mayrose Cornejo</last_name>
      <email>mcornejo@memorycentre.ca</email>
    </contact>
    <investigator>
      <last_name>Giovanni Marotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>JHSPH Center for Clinical Trials</investigator_affiliation>
    <investigator_full_name>Dave Shade</investigator_full_name>
    <investigator_title>Director, S-CitAD Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Agitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

